As efavirenz is commonly used to treat HIV-infected children, but there is only limited data available on its pharmacokinetics in African children, this study investigated its pharmacokinetics in 41 HIV-infected children in Uganda, who were treated with doses according to their body weight as recommended by WHO. Compared to adults, the children had lower and much more variable pharmacokinetic parameters; a significant percentage had subtherapeutic levels of the drug (although others had toxic levels).
Bakeera-Kitaka, S.; Natukunda, E.; Kendall, L.; Fillekes, Q.; Kekitiinwa, A.; Tumusiime, C.; Mugyenyi, P.; Walker, A.S.; Gibb, D.; Burger, D. Pharmacokinetics of Efavirenz dosed according to the WHO weight-bands in children in Uganda. Presented at The 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, USA, 16-19 February 2010. (2010)